Catalyst Wire Dossier Catalyst Wire Dossier

Zerbaxa (ceftolozane/tazobactam)

ceftolozane/tazobactam · Merck & Co.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Zerbaxa (ceftolozane/tazobactam), covering 2024-06-04 to 2026-01-21. Get the full timeline:

Most recent: Clinical Trial Update: Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation [Phase 4]

See pricing